@misc{10481/62085,
year = {2019},
url = {http://hdl.handle.net/10481/62085},
abstract = {To evaluate the use of amyloid-positron emission tomography (PET) in routine clinical practice, in a selected population with cognitive
impairment that meets appropriate use criteria (AUC).
A multicenter, observational, prospective case-series study of 211patients from 2 level-3 hospitals who fulfilled clinical AUC for
amyloid-PET scan in a naturalistic setting. Certainty degree was evaluated using a 5-point Likert scale: 0 (very low probability); 1 (low
probability); 2 (intermediate probability); 3 (high probability); and 4 (practically sure), before and after amyloid PET. The treatment plan
was considered as cognition-specific or noncognition-specific.
Amyloid-PET was positive in 118 patients (55.9%) and negative in 93 patients (44.1%). Diagnostic prescan confidence according
amyloid-PET results showed that in both, negative and positive-PET subgroup, the most frequent category was intermediate
probability (45.7% and 55.1%, respectively). After the amyloid-PET, the diagnostic confidence showed a very different distribution,
that was, in the negative-PET group the most frequent categories are very unlikely (70.7%) and unlikely (29.3%), while in the positive-
PET group were very probable (57.6%) and practically sure (39%). Only in 14/211 patients (6.6%) the result of the amyloid-PET did
not influence the diagnostic confidence, while in 194 patients (93.4%), the diagnostic confidence improved significantly after amyloid-
PET results. The therapeutic intention was modified in 93 patients (44.1%). Specific treatment for Alzheimer disease was started,
before amyloid-PET, in 80 patients (37.9%).
This naturalistic study provides evidence that the implementation of amyloid-PET is associated with a significant improvement in
diagnostic confidence and has a high impact on the therapeutic management of patients with mild cognitive impairment fulfilled
clinical AUC.},
publisher = {Wolters Kluwer Health, Inc},
keywords = {Alzheimer’s disease},
keywords = {Appropriate use criteria},
keywords = {Amyloid PET},
keywords = {Mild cognitive impairment},
keywords = {Florbetaben PET},
title = {Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria},
doi = {10.1097/MD.0000000000016509},
author = {Triviño Ibáñez, Eva María and Sánchez-Vañó, Raquel and Sopena Novales, Pablo and Romero Fábrega, Juan Carlos and Rodríguez Fernández, Antonio and Carnero Pardo, Cristóbal and Martínez Lozano, María Dolores and Gómez Río, Manuel},
}